Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

BOSTON, Aug. 30, 2024 /PRNewswire/ — Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk, is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET.

Further details, a webcast link, and a replay of the fireside chat will be posted on the company’s investor relations website at https://investors.ginkgobioworks.com/events.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats.  For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com

MEDIA CONTACT:

press@ginkgobioworks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-302234549.html

SOURCE Ginkgo Bioworks

Staff

Recent Posts

Standard Process Launches Cultivate, a New Practitioner Symposium Advancing Whole-Food Nutrition and Healthy Aging

Two immersive 2026 events in Seattle and Boston will offer up to 12 CE credits,…

35 minutes ago

Vericel Announces Preliminary 2025 Financial Results and Business Updates

Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth…

35 minutes ago

Stroke Experts Challenge “90-Day Recovery” Myth: New Research Shows Patients Need Long-Term Care

Study published by Centre for Neuro Skills researchers in Brain Injury journal argues current insurance…

35 minutes ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large,…

36 minutes ago

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as…

36 minutes ago

Picard / SynCardia Featured on the Cruxx of MedTech Podcast

TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard”…

36 minutes ago